1. Medtech Insight
  2. >>Digital Technologies
  3. >>AI

Migraine Relief Without A Pill: Click’s FDA Cleared CT-132 Turns Smartphone Into Therapy Tool

Click’s Platform Delivers CBT-Based Treatment Through AI-Powered Mobile Engagement

 
• By Shubham Singh

Built on Click’s AI-enabled platform, CT-132 delivers a 12-week behavioral intervention program rooted in multiple evidence-based techniques, including cognitive behavioral therapy (CBT) and bio-behavioral approaches. The goal: reduce brain hypersensitivity and enhance patients’ resilience to migraine triggers.

CT-132 can be prescribed for patients aged 18 and older and is intended for adjunctive use alongside acute/or other preventive treatments.
Key Takeaways

·CT-132 is the first FDA-authorized digital therapeutic for migraine prevention that works by targeting brain hypersensitivity and behavioral triggers, not just neurochemical pathways.

·Across two clinical trials, CT-132 demonstrated statistically significant reductions in monthly migraine days and improvements in quality-of-life metrics, even among CGRP non-responders.

·The strong efficacy data positions CT-132 for potential bundling with CGRP inhibitors under the FDA’s PDURS framework, paving the way for co-labeled digital-pharma products.

Click Therapeutics has turned a smartphone into a preventive tool for episodic migraine, a condition that affects over 37mn Americans alone.

With the US Food and Drug Administration granting de novo clearance for the first prescription-based digital therapeutic CT-132, Click has introduced a fundamentally different mechanism to treat migraine. Rather than...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from AI

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.